{"title":"Socioeconomic burden of multiple sclerosis: Insights from a cohort in Coimbra, Portugal","authors":"Inês Correia , Carolina Cunha , Catarina Bernardes , Gonçalo Carvalho , Alex Xavier , Carla Nunes , Carmo Macário , Lívia Sousa , Sónia Batista","doi":"10.1016/j.msard.2026.107083","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Multiple Sclerosis (MS) is the leading cause of non-traumatic disability in young adults, burdening patients, caregivers, and healthcare systems. In Portugal, annual direct healthcare costs for MS are estimated between €12,303 and €16,451, with total costs reaching €34,400 per patient. This study aims to characterize MS patients in Coimbra, focusing on demographic, clinical, and economic aspects to assess the disease's socioeconomic impact.</div></div><div><h3>Methods</h3><div>A cost-of-illness study with cross-sectional and retrospective components was conducted between 2021 and 2022 at the single referral center for MS in Coimbra. Patients completed a survey assessing sociodemographic, clinical, and economic data. Descriptive and comparative non-parametric analyses stratified by MS severity (mild EDSS 0–3.5, moderate 4–6.5, severe above 6.5) were performed.</div></div><div><h3>Results</h3><div>Among 163 patients (69.9 % female, mean age 48), 87.1 % had relapsing-remitting MS. Higher education was common (69.3 %), 45.4 % were married. Employment declined with disease severity; 9.4 % of mild EDSS patients were unemployed, while severe EDSS patients were retired. Average annual direct healthcare costs were €12,406, increasing with severity (€12,267 in mild MS to €16,020 in severe MS). Disease-modifying therapies accounted for most direct costs, although these declined in advanced stages, with hospitalization costs rising. Total costs per patient were €14,954 (mild MS), €28,289 (moderate MS), and €35,557 (severe MS), with relapses adding €3277 annually.</div></div><div><h3>Conclusion</h3><div>This study underscores the substantial economic burden of MS, particularly as disease severity progresses. Rising hospitalization and relapse costs highlight the need for cost-effective strategies and policies reducing MS-related socioeconomic impacts. Effective management could help mitigate these costs while improving outcomes.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"109 ","pages":"Article 107083"},"PeriodicalIF":3.0000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis and related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211034826001197","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Multiple Sclerosis (MS) is the leading cause of non-traumatic disability in young adults, burdening patients, caregivers, and healthcare systems. In Portugal, annual direct healthcare costs for MS are estimated between €12,303 and €16,451, with total costs reaching €34,400 per patient. This study aims to characterize MS patients in Coimbra, focusing on demographic, clinical, and economic aspects to assess the disease's socioeconomic impact.
Methods
A cost-of-illness study with cross-sectional and retrospective components was conducted between 2021 and 2022 at the single referral center for MS in Coimbra. Patients completed a survey assessing sociodemographic, clinical, and economic data. Descriptive and comparative non-parametric analyses stratified by MS severity (mild EDSS 0–3.5, moderate 4–6.5, severe above 6.5) were performed.
Results
Among 163 patients (69.9 % female, mean age 48), 87.1 % had relapsing-remitting MS. Higher education was common (69.3 %), 45.4 % were married. Employment declined with disease severity; 9.4 % of mild EDSS patients were unemployed, while severe EDSS patients were retired. Average annual direct healthcare costs were €12,406, increasing with severity (€12,267 in mild MS to €16,020 in severe MS). Disease-modifying therapies accounted for most direct costs, although these declined in advanced stages, with hospitalization costs rising. Total costs per patient were €14,954 (mild MS), €28,289 (moderate MS), and €35,557 (severe MS), with relapses adding €3277 annually.
Conclusion
This study underscores the substantial economic burden of MS, particularly as disease severity progresses. Rising hospitalization and relapse costs highlight the need for cost-effective strategies and policies reducing MS-related socioeconomic impacts. Effective management could help mitigate these costs while improving outcomes.
期刊介绍:
Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource.
A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.